GSK vs PFE
GSK plc and Pfizer, both Healthcare
Pfizer is the larger company at $144B against $104B. Over the past year PFE returned +23% against +17% for GSK. The RyuScore puts GSK ahead, 67 against 61 out of 100.
| Figure | GSK | PFE |
|---|---|---|
| Last close | $46.51 | $28.27 |
| Market cap | $104B | $144B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 37.2 |
| Dividend yield | n/a | 6.2% |
| 1-year return | +17% | +23% |
| 5-year return | +43% | -19% |
| RyuScoresector-relative, 1–10 | 67/100 | 61/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
GSK plc
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.